central pharmacies (uk) limited Company Information
Company Number
SC230534
Website
-Registered Address
suite 4, pavilion 3, st james business park, paisley, PA3 3BB
Industry
Dispensing chemist in specialised stores
Telephone
01412216201
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
qpp holdings limited 100%
central pharmacies (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of CENTRAL PHARMACIES (UK) LIMITED at £1.8m based on a Turnover of £6.2m and 0.29x industry multiple (adjusted for size and gross margin).
central pharmacies (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of CENTRAL PHARMACIES (UK) LIMITED at £4.7m based on an EBITDA of £1.2m and a 3.97x industry multiple (adjusted for size and gross margin).
central pharmacies (uk) limited Estimated Valuation
Pomanda estimates the enterprise value of CENTRAL PHARMACIES (UK) LIMITED at £8.9m based on Net Assets of £3.9m and 2.27x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Central Pharmacies (uk) Limited Overview
Central Pharmacies (uk) Limited is a live company located in paisley, PA3 3BB with a Companies House number of SC230534. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in April 2002, it's largest shareholder is qpp holdings limited with a 100% stake. Central Pharmacies (uk) Limited is a mature, mid sized company, Pomanda has estimated its turnover at £6.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Central Pharmacies (uk) Limited Health Check
Pomanda's financial health check has awarded Central Pharmacies (Uk) Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 4 areas for improvement. Company Health Check FAQs
5 Strong
3 Regular
4 Weak
Size
annual sales of £6.2m, make it smaller than the average company (£12.1m)
- Central Pharmacies (uk) Limited
£12.1m - Industry AVG
Growth
3 year (CAGR) sales growth of 14%, show it is growing at a faster rate (5.4%)
- Central Pharmacies (uk) Limited
5.4% - Industry AVG
Production
with a gross margin of 31.9%, this company has a comparable cost of product (31.9%)
- Central Pharmacies (uk) Limited
31.9% - Industry AVG
Profitability
an operating margin of 18.3% make it more profitable than the average company (3.4%)
- Central Pharmacies (uk) Limited
3.4% - Industry AVG
Employees
with 53 employees, this is below the industry average (84)
53 - Central Pharmacies (uk) Limited
84 - Industry AVG
Pay Structure
on an average salary of £22k, the company has an equivalent pay structure (£22k)
- Central Pharmacies (uk) Limited
£22k - Industry AVG
Efficiency
resulting in sales per employee of £116.7k, this is less efficient (£139.2k)
- Central Pharmacies (uk) Limited
£139.2k - Industry AVG
Debtor Days
it gets paid by customers after 44 days, this is later than average (31 days)
- Central Pharmacies (uk) Limited
31 days - Industry AVG
Creditor Days
its suppliers are paid after 79 days, this is slower than average (69 days)
- Central Pharmacies (uk) Limited
69 days - Industry AVG
Stock Days
it holds stock equivalent to 29 days, this is in line with average (30 days)
- Central Pharmacies (uk) Limited
30 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 75 weeks, this is more cash available to meet short term requirements (15 weeks)
75 weeks - Central Pharmacies (uk) Limited
15 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 32.4%, this is a lower level of debt than the average (61.7%)
32.4% - Central Pharmacies (uk) Limited
61.7% - Industry AVG
CENTRAL PHARMACIES (UK) LIMITED financials
Central Pharmacies (Uk) Limited's latest turnover from March 2023 is estimated at £6.2 million and the company has net assets of £3.9 million. According to their latest financial statements, Central Pharmacies (Uk) Limited has 53 employees and maintains cash reserves of £2.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | ||||||||||||||
Other Income Or Grants | ||||||||||||||
Cost Of Sales | ||||||||||||||
Gross Profit | ||||||||||||||
Admin Expenses | ||||||||||||||
Operating Profit | ||||||||||||||
Interest Payable | ||||||||||||||
Interest Receivable | ||||||||||||||
Pre-Tax Profit | ||||||||||||||
Tax | ||||||||||||||
Profit After Tax | ||||||||||||||
Dividends Paid | ||||||||||||||
Retained Profit | ||||||||||||||
Employee Costs | ||||||||||||||
Number Of Employees | 53 | 53 | 49 | 49 | 49 | 49 | 46 | 45 | ||||||
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 478,941 | 501,318 | 464,290 | 447,467 | 350,205 | 119,514 | 123,569 | 143,544 | 168,004 | 172,067 | 93,265 | 104,855 | 251,850 | 271,113 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 44,307 | 177,241 | 310,174 | 805,244 | 1,187,724 | 1,020,759 | 1,350,069 | 2,138,700 | 2,568,009 |
Investments & Other | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 479,041 | 501,418 | 464,390 | 447,567 | 350,305 | 163,921 | 300,810 | 453,718 | 973,248 | 1,359,791 | 1,114,024 | 1,454,924 | 2,390,550 | 2,839,122 |
Stock & work in progress | 339,541 | 358,921 | 351,878 | 414,869 | 315,721 | 343,280 | 336,735 | 316,367 | 352,673 | 326,864 | 290,775 | 298,084 | 390,306 | 357,911 |
Trade Debtors | 758,026 | 559,688 | 412,586 | 445,447 | 404,272 | 455,314 | 371,462 | 479,299 | 782,689 | 871,152 | 682,866 | 491,115 | 703,582 | 653,411 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 2,044,843 | 1,780,209 | 2,561,893 | 426,730 | 322,737 | 359,109 | 430,264 | 423,897 | 55,929 | 4,821 | 5,035 | 3,635 | 0 | 0 |
Cash | 2,164,604 | 1,890,017 | 2,376,413 | 2,068,348 | 1,956,555 | 1,753,236 | 1,528,928 | 831,409 | 525,758 | 419,773 | 999,758 | 1,226,748 | 417,544 | 506,155 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 5,307,014 | 4,588,835 | 5,702,770 | 3,355,394 | 2,999,285 | 2,910,939 | 2,667,389 | 2,050,972 | 1,717,049 | 1,622,610 | 1,978,434 | 2,019,582 | 1,511,432 | 1,517,477 |
total assets | 5,786,055 | 5,090,253 | 6,167,160 | 3,802,961 | 3,349,590 | 3,074,860 | 2,968,199 | 2,504,690 | 2,690,297 | 2,982,401 | 3,092,458 | 3,474,506 | 3,901,982 | 4,356,599 |
Bank overdraft | 135,772 | 132,104 | 0 | 52,064 | 144,400 | 178,916 | 120,664 | 117,232 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 914,127 | 870,902 | 829,515 | 1,011,507 | 837,074 | 908,716 | 792,718 | 744,113 | 1,020,353 | 1,467,877 | 1,003,903 | 937,630 | 1,306,051 | 1,239,269 |
Group/Directors Accounts | 0 | 0 | 0 | 243,811 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 432,623 | 587,805 | 2,187,796 | 194,505 | 495,373 | 441,049 | 976,091 | 97,859 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 1,482,522 | 1,590,811 | 3,017,311 | 1,501,887 | 1,476,847 | 1,528,681 | 1,889,473 | 959,204 | 1,020,353 | 1,467,877 | 1,003,903 | 937,630 | 1,306,051 | 1,239,269 |
loans | 353,662 | 491,601 | 0 | 0 | 53,636 | 200,522 | 176,908 | 299,729 | 0 | 0 | 0 | 0 | 161,515 | 294,145 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418,396 | 218,089 | 507,101 | 752,817 | 1,520,546 | 1,756,252 |
provisions | 36,221 | 34,535 | 32,031 | 29,268 | 10,498 | 11,286 | 11,512 | 14,334 | 18,835 | 12,451 | 5,872 | 7,191 | 8,165 | 10,995 |
total long term liabilities | 389,883 | 526,136 | 32,031 | 29,268 | 64,134 | 211,808 | 188,420 | 314,063 | 437,231 | 230,540 | 512,973 | 760,008 | 1,690,226 | 2,061,392 |
total liabilities | 1,872,405 | 2,116,947 | 3,049,342 | 1,531,155 | 1,540,981 | 1,740,489 | 2,077,893 | 1,273,267 | 1,457,584 | 1,698,417 | 1,516,876 | 1,697,638 | 2,996,277 | 3,300,661 |
net assets | 3,913,650 | 2,973,306 | 3,117,818 | 2,271,806 | 1,808,609 | 1,334,371 | 890,306 | 1,231,423 | 1,232,713 | 1,283,984 | 1,575,582 | 1,776,868 | 905,705 | 1,055,938 |
total shareholders funds | 3,913,650 | 2,973,306 | 3,117,818 | 2,271,806 | 1,808,609 | 1,334,371 | 890,306 | 1,231,423 | 1,232,713 | 1,283,984 | 1,575,582 | 1,776,868 | 905,705 | 1,055,938 |
Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | ||||||||||||||
Operating Profit | ||||||||||||||
Depreciation | 41,301 | 48,864 | 38,466 | 36,940 | 16,609 | 19,369 | 20,517 | 25,492 | 21,166 | 16,098 | 13,022 | 15,921 | 21,097 | 25,913 |
Amortisation | 0 | 0 | 0 | 0 | 44,307 | 132,934 | 132,933 | 495,070 | 382,480 | 364,757 | 329,310 | 329,310 | 429,309 | 429,309 |
Tax | ||||||||||||||
Stock | -19,380 | 7,043 | -62,991 | 99,148 | -27,559 | 6,545 | 20,368 | -36,306 | 25,809 | 36,089 | -7,309 | -92,222 | 32,395 | 357,911 |
Debtors | 462,972 | -634,582 | 2,102,302 | 145,168 | -87,414 | 12,697 | -101,470 | 64,578 | -37,355 | 188,072 | 193,151 | -208,832 | 50,171 | 653,411 |
Creditors | 43,225 | 41,387 | -181,992 | 174,433 | -71,642 | 115,998 | 48,605 | -276,240 | -447,524 | 463,974 | 66,273 | -368,421 | 66,782 | 1,239,269 |
Accruals and Deferred Income | -155,182 | -1,599,991 | 1,993,291 | -300,868 | 54,324 | -535,042 | 878,232 | 97,859 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 1,686 | 2,504 | 2,763 | 18,770 | -788 | -226 | -2,822 | -4,501 | 6,384 | 6,579 | -1,319 | -974 | -2,830 | 10,995 |
Cash flow from operations | ||||||||||||||
Investing Activities | ||||||||||||||
capital expenditure | ||||||||||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | ||||||||||||||
Financing Activities | ||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | -243,811 | 243,811 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | -137,939 | 491,601 | 0 | -53,636 | -146,886 | 23,614 | -122,821 | 299,729 | 0 | 0 | 0 | -161,515 | -132,630 | 294,145 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -418,396 | 200,307 | -289,012 | -245,716 | -767,729 | -235,706 | 1,756,252 |
share issue | ||||||||||||||
interest | ||||||||||||||
cash flow from financing | ||||||||||||||
cash and cash equivalents | ||||||||||||||
cash | 274,587 | -486,396 | 308,065 | 111,793 | 203,319 | 224,308 | 697,519 | 305,651 | 105,985 | -579,985 | -226,990 | 809,204 | -88,611 | 506,155 |
overdraft | 3,668 | 132,104 | -52,064 | -92,336 | -34,516 | 58,252 | 3,432 | 117,232 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 270,919 | -618,500 | 360,129 | 204,129 | 237,835 | 166,056 | 694,087 | 188,419 | 105,985 | -579,985 | -226,990 | 809,204 | -88,611 | 506,155 |
central pharmacies (uk) limited Credit Report and Business Information
Central Pharmacies (uk) Limited Competitor Analysis
Perform a competitor analysis for central pharmacies (uk) limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
central pharmacies (uk) limited Ownership
CENTRAL PHARMACIES (UK) LIMITED group structure
Central Pharmacies (Uk) Limited has 1 subsidiary company.
Ultimate parent company
1 parent
CENTRAL PHARMACIES (UK) LIMITED
SC230534
1 subsidiary
central pharmacies (uk) limited directors
Central Pharmacies (Uk) Limited currently has 2 directors. The longest serving directors include Mr Gavin McLaren (Apr 2002) and Mr Parvez Aslam (Apr 2002).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Gavin McLaren | Scotland | 52 years | Apr 2002 | - | Director |
Mr Parvez Aslam | Scotland | 63 years | Apr 2002 | - | Director |
P&L
March 2023turnover
6.2m
+15%
operating profit
1.1m
0%
gross margin
32%
-0.78%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
3.9m
+0.32%
total assets
5.8m
+0.14%
cash
2.2m
+0.15%
net assets
Total assets minus all liabilities
central pharmacies (uk) limited company details
company number
SC230534
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
April 2002
age
22
accounts
Total Exemption Full
ultimate parent company
previous names
N/A
incorporated
UK
address
suite 4, pavilion 3, st james business park, paisley, PA3 3BB
last accounts submitted
March 2023
central pharmacies (uk) limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to central pharmacies (uk) limited. Currently there are 1 open charges and 0 have been satisfied in the past.
central pharmacies (uk) limited Companies House Filings - See Documents
date | description | view/download |
---|